Novartis

3 Best Biotech Acquisitions of 2018 (So Far)
3 Best Biotech Acquisitions of 2018 (So Far)
Motley Fool
M&A
biotech
Celgene
Juno Therapeutics
Novartis
AveXis
Roche
Foundation Medicine
Flag link:
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig: expert
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig: expert
Fierce Pharma
migraines
Amgen
Novartis
Aimovig
Flag link:
Novartis dumps worldwide rights to an Aveo drug, and the little biotech is not happy with them
Novartis dumps worldwide rights to an Aveo drug, and the little biotech is not happy with them
Endpoints
Novartis
Aveo
GDF15
AV-380
Flag link:
Novartis steps in to compete with Mylan’s Epipen
Novartis steps in to compete with Mylan’s Epipen
Drug Delivery Business News
Adamis Pharmaceuticals
Novartis
Sandoz
Symjepi
Mylan
EpiPens
Flag link:
Novartis chairman says Alcon worth $20 billion -$30 billion - Finanz und Wirtschaft
Novartis chairman says Alcon worth $20 billion -$30 billion - Finanz und Wirtschaft
Yahoo/Reuters
Novartis
Alcon
M&A
Flag link:
Novartis to spin out Alcon ophthalmic subsidiary
Novartis to spin out Alcon ophthalmic subsidiary
Mass Device
Novartis
Alcon
opthalmology
eye health
devices
spinoffs
Flag link:
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Endpoints
Eli Lilly
Taltz
Novartis
ankylosing spondylitis
Cosentyx
Flag link:
Novartis pads Cosentyx's psoriatic arthritis lead with joint-damage label update
Novartis pads Cosentyx's psoriatic arthritis lead with joint-damage label update
Fierce Pharma
Novartis
Cosentyx
psoriatic arthritis
Flag link:
5 Experimental New Drugs That Could Be Worth $47 Billion
5 Experimental New Drugs That Could Be Worth $47 Billion
Motley Fool
GSK2857916
GSK
brolucizumab
Novartis
aducanumab
Biogen
upadacatinib
AbbVie
VX-659 + tezacaftor + ivacaftor
Vertex Pharmaceuticals
Flag link:
Novartis touts effectiveness, safety of autoimmune drug copies
Novartis touts effectiveness, safety of autoimmune drug copies
Yahoo/Reuters
Novartis
biosimilars
JNJ
Remicade
Amgen
Enbrel
autoimmune disease
Flag link:
Amid tough competition, Novartis makes case for rheumatology drug Cosentyx
Amid tough competition, Novartis makes case for rheumatology drug Cosentyx
Pharmaforum
Novartis
Cosentyx
ankylosing spondylitis
Flag link:
Is the future of therapy online? Swiss drug giant Novartis thinks so
Is the future of therapy online? Swiss drug giant Novartis thinks so
Marketwatch
Novartis
Pear Therapeutics
digital therapeutics
Flag link:
Swiss Won’t Investigate Novartis Over Payments to Cohen
Swiss Won’t Investigate Novartis Over Payments to Cohen
Bloomberg
Novartis
Switzerland
Donald Trump
Michael Cohen
Flag link:
Migraine Breakthrough: Not So Fast
Migraine Breakthrough: Not So Fast
Forbes
Amgen
Novartis
Aimovig
migraines
adults
monoclonal antibodies
Flag link:
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Fierce Pharma
Novartis
Kisqali
metastatic breast cancer
ASCO 2018
HR-positive
HER2-negative breast cancer
Flag link:
NTC acquires part of Novartis’ ophthalmic portfolio
NTC acquires part of Novartis’ ophthalmic portfolio
GoinPharma
Novartis
NTC
ophthalmology
M&A
Flag link:
How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
Investors Business Daily
AbbVie
Novartis
Humira
biosimilars
Europe
CHMP
Flag link:
Novartis receives EU approval for biosimilar Zessly
Novartis receives EU approval for biosimilar Zessly
Reuters
Novartis
Sandoz
biosimilars
Europe
Zessly
Flag link:
Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200
Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200
Fierce Pharma
Novartis
AveXis
gene therapy
drug manufacturing
Flag link:
Cohen scandal disrupts ex-Novartis CEO's move to hedge fund board: WSJ
Cohen scandal disrupts ex-Novartis CEO's move to hedge fund board: WSJ
Fierce Pharma
Novartis
Joe Jimenez
Donald Trump
Michael Cohen
Flag link:

Pages